

EFFECTS OF BLEOMYCIN ON PHA-STIMULATED LYMPHOCYTES AND ISOLATED HEPATIC NUCLEI*

GEORGE P. SARTIANO, ALAN WINKELSTEIN, WILLIAM LYNCH
and SALLIE S. BOGGS**

Division of Hematology, Department of Medicine (Presbyterian-University
Hospital and Montefiore Hospital) and
Department of Anatomy and Cell Biology, University of Pittsburgh School of Medicine,
Pittsburgh, Pennsylvania 15261, U.S.A.

(Received for publication September 5, 1972)

Experiments were carried out in which lymphocytes stimulated by phytohemagglutinin were exposed during 3-day culture to concentrations of bleomycin varying from 0.0 to 300 $\mu\text{g}/\text{ml}$. Inhibition of one hour ^3H -thymidine incorporation in these 72-hour cultures increased as the concentration of bleomycin increased from 1.5 $\mu\text{g}/\text{ml}$ (14.1% inhibition) to 300 $\mu\text{g}/\text{ml}$ (96.4% inhibition), and was a linear function when dose and percent control ^3H -thymidine uptake were plotted logarithmically. In 3 of 9 experiments, ^3H -thymidine uptake at the 1.5 $\mu\text{g}/\text{ml}$ dose was increased. This increase was not statistically significant, but the possibility of sublethal DNA damage followed by repair was raised. Exposure of resting lymphocytes to bleomycin in the absence of PHA showed no significant increase above baseline thymidine uptake. Addition of bleomycin to cultures at 24 and 48 hours after the addition of PHA produced the same quantitative reduction in uptake of thymidine at 70 hours as the same concentration added at zero time, suggesting that the effect of bleomycin is independent of the initial stimulatory events resulting from the addition of PHA.

Evidence of a repair-like process following damage by bleomycin was observed in a different system utilizing isolated hepatic nuclei. A two to five fold increase of thymidine tri-phosphate incorporation was obtained in response to addition of bleomycin in this isolated nuclear system (rat liver nuclei). This process was time and dose related and continued for at least one hour in the presence of bleomycin.

These results demonstrate that bleomycin causes dose-dependent reduction of DNA synthesis in PHA-stimulated lymphocytes. Furthermore, they suggest that DNA damage caused by low concentrations of bleomycin may be repaired, and that when damage exceeds the cell's ability to repair, cell death results.

Effects of bleomycin on PHA-stimulated lymphocytes

Human peripheral blood lymphocytes stimulated by phytohemagglutinine *in vitro* undergo "blastogenesis"¹⁻⁴⁾ and synthesize DNA, RNA and proteins⁵⁻⁷⁾. This *in vitro* system of proliferating lymphoid cells has been used to evaluate the kinetics of lymphocyte proliferation⁸⁾, the immunologic functions of lymphocytes⁹⁾, and the effects of chemotherapeutic agents¹⁰⁻¹³⁾.

Bleomycin is a glycopeptide antibiotic derived from cultures of *Streptomyces verticillus* by UMEZAWA and co-workers¹⁴⁾. The anti-neoplastic character of this agent has been demonstrated in a spectrum of animal neoplasms¹⁵⁻¹⁶⁾. Clinical trials with bleomycin have shown it to be useful in the treatment of lymphomas and some squamous tumors¹⁷⁻²⁰⁾.

The experiments described below were conducted in order to quantitate the effects of bleomycin

* This work is supported by Institutional Grant IN-58L from the American Cancer Society, a research grant (No. AM14352-04) from the National Institute of Arthritis and Metabolic Diseases, and a grant from the Health Research Services Foundation of Western Pennsylvania (N-62).

** Special Fellow of the Leukemia Society of America.

upon proliferating lymphocytes in the PHA-stimulated system.

While studying the activity of bleomycin in this system, it became evident that another laboratory model, comprised of isolated hepatic nuclei⁽²¹⁻²⁶⁾ was also useful in studying the DNA-damaging effects of bleomycin, and experiments utilizing this system are also described.

Materials and Methods

The procedures employed in these experiments have been described in detail⁽²¹⁻²⁴⁾ and will be reviewed only briefly.

1. Lymphocyte Cultures

Venous blood samples were sedimented by means of high molecular weight dextran. The leukocyte-rich supernatant was removed and centrifuged and the cell sediment was resuspended in TC199 (8 ml) and fetal calf serum (FCS, 2.0 ml). Cell counts were adjusted by dilution with FCS to $7.5\sim 15\times 10^6$ /ml. Each culture contained 7.8 ml of TC199, 2.25 ml of FCS, and streptomycin (100 μ g/ml) and penicillin (100 units/ml). Those cultures to which PHA was added contained 0.1 ml of PHA (Burroughs Wellcome). Bleomycin complex* was dissolved in saline and added to cultures just prior to phytohemagglutinin. Each concentration was set up in triplicate with appropriate controls.

Thymidine (New England Nuclear Corporation, ³H-Tdr, (sp. act. 6.7 curies/m mole) 1.0 μ Ci per 5×10^6 cells, was added to each culture one hour before termination of the experiment. For analysis, cells were washed twice in phosphate-buffered saline (pH 7.9) and centrifuged. They were resuspended and then precipitated and washed three times with cold 5% trichloroacetic acid. The insoluble residue was then washed in methanol, dissolved in 0.5 ml Soluene^R and mixed with 10 ml Liquifluor^R (New England Nuclear)-toluene in preparation for counting in a Packard Scintillation counter. Each sample was counted for 5 minutes and activity calculated by subtracting background counts.

Results were expressed as cpm/ 10^6 cells; values for replicate determinations were averaged and standard errors calculated.

2. Isolated Rat Liver Nuclei

Liver samples (about 1 g) were rinsed in 0.3 M sucrose and suspended in 15 to 20 volumes of 0.3 M sucrose — 4×10^{-8} M CaCl₂ with one stroke in a loose Dounce homogenizer. The suspension was then homogenized with a loose fitting rubber pestle, filtered through a monofilament nylon screen (110 mesh), and centrifuged at $750\times g$ for 4 minutes. The resulting pellet was resuspended in 18 ml of 2 M sucrose — 10^{-8} M CaCl₂, layered over 13 ml of 2.2 M sucrose, and sedimented by centrifugation for 20 minutes in a Spinco SW25.1 rotor at 20,000 rpm. Finally, the nuclei were suspended in 2.5 ml of 0.3 M sucrose, and used immediately.

Reactions were stopped with 1 ml of 1 M NaOH, and DNA was precipitated with 5 ml of a suspension of 40 mg of Celite (Johns-Manville) in ice-cold trichloroacetic acid (10%). The DNA was dissolved three times (0.3 ml of 1 M NaOH) and precipitated (8 ml of 5% trichloroacetic acid), and the final precipitate, dissolved in 1 ml of 1 M NaOH, was heated at 80°C for 15 minutes. Finally, the DNA was precipitated with trichloroacetic acid on a pad of Celite and the precipitate was washed with acid, ethanol and ether.

DNA was estimated with diphenylamine⁽²²⁾ and radioactivity was measured in a hyamine-toluene liquid scintillation mixture, as described above.

Results

The addition of bleomycin complex to lymphoblast cultures inhibited ³H-thymidine uptake progressively as the concentration was increased. The curve depicting inhibition took the form of a typical linear "cell-kill" curve in the concentration-range between 1.5 μ g/ml and 300 μ g/ml when

* Supplied by Dr. KARL AGRE, Director of Clinical Pharmacology, Bristol Laboratories, Syracuse, New York.

Fig. 1. One-hour ^3H Tdr uptake of PHA-stimulated lymphocytes cultured with varying concentrations of bleomycin for 72 hours.

Each point represents a mean of 9~27 separate determinations, plotted as percent of thymidine uptake of respective control specimens for that experiment. Standard error is indicated by barred vertical lines




Table 1

Time after PHA bleomycin added	Total time bleomycin present	^3H Tdr-CPM/ 10^6 cells
Zero Time	72 hours	264
24 hours	48 hours	278
48 hours	24 hours	259
70 hours	2 hours	2,010
Control	0 hour	2,001

Effect of bleomycin added at varying times after PHA during 3-day culture period: Bleomycin (150 $\mu\text{g}/\text{ml}$ final concentration) was added to cultures at zero time, 24, 48 and 70 hours. Thymidine was added to all cultures 2 hours before termination, and all cultures were harvested in the usual manner at 72 hours. (All determinations were carried out in duplicate.)

Table 2. ^3H -Thymidine uptake of cultures containing 1.5 $\mu\text{g}/\text{ml}$ bleomycin for 72 hours

Specimen	Mean CPM ^3H Tdr/ 10^6 cells* (\pm S.E.)	Mean control ^3H Tdr/ 10^6 cells (\pm S.E.)	^3H Tdr uptake % of control (\pm S.E. of ratio)
MA	319 \pm 122	975 \pm 195	32.8 \pm 12.9
TBL	672 \pm 303	1,567 \pm 393	42.9 \pm 23.1
AW	1,090 \pm 90	2,640	41.3 \pm 34.0
GS	664 \pm 101	623 \pm 53	107 \pm 18.6
JW	433 \pm 134	761 \pm 332	56.9 \pm 36.4
JM	452 \pm 49	698 \pm 340	64.8 \pm 42.1
RM	1,021 \pm 79	736 \pm 207	138.7 \pm 43.7
SA	1,450 \pm 244	970	149.5 \pm 25.1
MW	1,373 \pm 71	804 \pm 195	168 \pm 43.2

* Each mean value represents 3 separate determinations.

concentration of bleomycin and percent ^3H -thymidine uptake were plotted logarithmically (Fig. 1). In order to determine whether or not bleomycin affected the events necessary for PHA stimulation of the lymphocytes, the agent was added at various times after addition of PHA. The addition of bleomycin (150 $\mu\text{g}/\text{ml}$) to cultures 24 and 48 hours after the addition of PHA produced the same quantitative reduction in uptake of thymidine at 70 hours as this concentration added at zero time (Table 1). Exposure of unstimulated, freshly isolated lymphocytes to concentrations of bleomycin varying from 1.5 to 1,500 $\mu\text{g}/\text{ml}$ showed no significant alteration in baseline thymidine uptake.


At the lowest concentrations of bleomycin used in 72-hour cultures (1.5 $\mu\text{g}/\text{ml}$), inhibition of ^3H -thymidine incorporation into lymphoblasts was not seen in four of nine experiments. In these experiments there was either no effect or apparent stimulation of incorporation (up to 168 % of the control value) (Table 2). Although these determinations were not significantly different from 100 %

Fig. 2. Effect of bleomycin on ³H-TTP incorporation by normal isolated rat liver nuclei

Experiment A: Effect of 1.5 mg/ml bleomycin on ³H-TTP uptake as a function of time; 9.7 × 10⁶ nuclei/tube, incubation times 0~60 minutes.

Experiment B: Effect of varying concentrations of bleomycin (0~1,500 µg/ml) on ³H-TTP uptake with incubation time fixed at 1 hour; 8.0 × 10⁶ nuclei/tube.

Reaction mixture (0.5 ml): 0.1 M Tris (pH 7.4), 4 × 10⁻³ M MgCl₂, 1.6 × 10⁻² M KCl, 2 × 10⁻³ M ATP, d GTP, d CTP, d ATP (each 8 × 10⁻⁵ M), 1.6 × 10⁻⁵ M ³H-TTP (0.5 Ci per m mole), and the suspension of intact nuclei (containing 50~100 mcg of DNA).



as determined by analysis of variance of the ratio, they opened the question as to whether or not repair of DNA following damage due to bleomycin might be occurring.

Since one mechanism of action of bleomycin appears to be through direct scission of single stranded DNA²⁵⁾ it seemed likely that the readily quantitated isolated hepatic nuclear system might provide a useful tool for evaluating these effects. Therefore, the effect of bleomycin in varying doses (1.5~1,500 µg/ml) and over varying time spans (up to 1 hour) upon isolated hepatic nuclei, were studied. The addition of bleomycin to isolated rat liver nuclei caused an approximately 2~5 fold increase of ³H-thymidine triphosphate (³H-TTP) incorporation. At a concentration of 1,500 µg/ml, incorporation increased linearly over a one hour period of incubation (Fig. 2A), producing a five-fold increment over control values at the end of the incubation period. One hour incorporation of ³H-TTP was dose-related in the range of concentrations between 0.75 µg/ml and 1,500 µg/ml (Fig. 2B).

Table 3

Reference	Cell type	Bleomycin fraction	Conc. $\mu\text{g/ml}$	Length of incubation	$^3\text{H-Tdr}$ % of control uptake
KUNIMOTO, <i>et al.</i> ²⁶⁾	HeLa S-3	Bleomycin complex	0.5	9 hours	90.5
			1.0		62.9
			10.0		33.0
			100.0		10.2
SUZUKI, <i>et al.</i> ²⁵⁾	EHRlich ascites	A ₂	40	30 minutes	70
	HeLa S-3	A ₂	40	4 hours	79
				28 hours	43
UMEZAWA, <i>et al.</i> ¹⁷⁾	<i>E. coli</i> B	A ₂	2		73.2
			10		70.6
	HeLa cells	A ₂	50		51.7
			50		39.5

Discussion

The present studies demonstrate that bleomycin is an effective inhibitor of ^3H -thymidine uptake in normal human lymphocytes undergoing blastogenesis. The amount of inhibition is dose-related and takes a linear form when both variables are plotted logarithmically.

These results are consistent with the findings of other investigations studying the effects of bleomycin complex and its sub-fractions upon several cell systems *in vitro*, as summarized in Table 3. KUNIMOTO²⁶⁾ performed a quantitative study in which the effects of bleomycin on DNA synthesis in HeLa S-3 cells yielded results similar to the present experiment (Table 3, line a). SUZUKI and co-workers²⁵⁾ observed "significant inhibition" of growth of HeLa S-3 cells and *Escherichia coli* B at concentrations of bleomycin as low as 1.0 $\mu\text{g/ml}$, and described inhibition of ^3H -thymidine uptake in both EHRlich ascites cells and HeLa cells incubated with bleomycin at a concentration of 40 $\mu\text{g/ml}$ for varying lengths of time (Table 3, line b). Similarly, UMEZAWA and co-workers¹⁷⁾ reported inhibition of ^3H -thymidine incorporation into DNA of intact *E. coli* B and HeLa cells at concentrations of bleomycin varying from 2 to 50 $\mu\text{g/ml}$ (Table 3, line c).

Working with DNA isolated from *E. coli* 15T⁻ cells and HeLa cells, and with whole *E. coli* 15T⁻, SUZUKI *et al.* demonstrated that bleomycin produces scission of single-stranded DNA, both *in vitro* and *in vivo*²⁵⁾. TOBEY²⁷⁾ demonstrated that in Chinese hamster cells exposed to bleomycin at a concentration of 100 $\mu\text{g/ml}$ *in vitro*, initiation and termination of DNA synthesis occur at normal rates, but cells accumulate in G₂. NAGATSU *et al.*²⁸⁾ similarly demonstrated that a large fraction of transplanted VX-2 carcinoma cells treated with bleomycin ended up with a G₂ content of DNA.

The presently reported results with lymphocytes are similar to those reported by UMEZAWA¹⁷⁾, SUZUKI²⁵⁾, and KUNIMOTO²⁶⁾, in that there was dose-dependent and time-dependent inhibition of DNA synthesis following exposure of PHA-stimulated lymphocytes to bleomycin for 72 hours *in vitro*. Exposure of unstimulated, freshly isolated lymphocytes to concentrations of bleomycin varying from 1.5 to 1,500 $\mu\text{g/ml}$ showed no significant alteration in baseline thymidine uptake. (Baseline measurements in the system are very low, and *small* increments or decrements may not have been detectable; however, no evidence of increased thymidine uptake suggesting repair was noted.) Since the recorded reduction in thymidine uptake by PHA-stimulated lymphocytes was the same at 72 hours for cultures to which bleomycin (150 $\mu\text{g/ml}$) was added at zero time, 24 hours and 48 hours, the effect of bleomycin seems to be independent of the early events of entry into the cell cycle stimulated by PHA and occurring in the first 24~48 hours. No reduction in incorporation was seen when bleomycin was added 2 hours before ^3H -thymidine on day 3 of this experiment. The explicit point of action of bleomycin in the cell cycle was not further determined by these experiments.

In attempting to further delineate the significance of the apparently increased uptake of thymidine noted at low dose (1.5 $\mu\text{g/ml}$) levels of bleomycin in several experiments, studies were carried out in

which the effects of bleomycin upon isolated hepatic nuclei were investigated. A linear, dose-related and time-related increase in incorporation of thymidine tri-phosphate into DNA ("unscheduled" DNA synthesis) was demonstrated. Since nuclei in this system do not exhibit significant replicative DNA synthesis *in vitro* unless the cells have been previously perturbed in the experimental animal, the increased incorporation resulting on incubation with bleomycin is not attributed to stimulation of replicative DNA synthesis.

These results suggest that this system can simultaneously sustain and repair DNA damage caused by bleomycin. Since one action of bleomycin appears to be scission of single-stranded DNA²⁵⁾ it is suggested that stimulation of thymidine uptake seen in isolated rat liver nuclei represents repair of single-stranded DNA breaks.

Stimulation of thymidine incorporation into DNA as a result of repair of DNA damage seems to be a general cellular function, and has been reported to result from exposure of bacteria and lymphocytes to ultraviolet radiation²⁹⁻³¹⁾, carcinogens and alkylating agents³²⁾. It is therefore not surprising that an agent such as bleomycin, which apparently causes single-stranded DNA breaks as one mode of action, might produce damage which would secondarily result in DNA repair. These data also suggest that cell death may ensue as the result of bleomycin-induced DNA damage when the cell's capacity to repair this damage is exceeded.

The ability or lack of ability to repair DNA damage may, therefore, in part, determine the sensitivity of a given cell to bleomycin. Bleomycin has been shown to have minimal toxic effects on non-lymphoid cell lines of the hematopoietic system. This could be related to a superior ability of non-lymphoid cells to repair single-stranded DNA breaks.

The present studies suggest that the investigation of sensitivity of neoplastic lymphoid cell lines to bleomycin *in vitro* may assist in evaluating the potential response to bleomycin.

Acknowledgements

We gratefully acknowledge the excellent technical assistance of Ms. MARILYN WALTER and Mr. LEWIS HAMELLE, Jr.

References

- 1) HUNGERFORD, D. A.; A. J. DONNELLY, P. C. NOWELL & S. BECK: The chromosome constitution of a human phenotype intersex. *Amer. J. Human Genetics* 11 : 215~236, 1959
- 2) NOWELL, P. C.: Phytohemagglutinin: An initiator of mitosis in cultures of normal human leukocytes. *Cancer Res.* 20 : 462~466, 1960
- 3) COOPER, E. H.; P. BARKHAN & A. J. HALE: Mitogenic activity of phytohemagglutinin. *Lancet* 1961-II : 210, 1961
- 4) CARSTAIRS, K.: Transformation of the small lymphocyte in culture. *Lancet* 1961-II : 984, 1961
- 5) MCINTYRE, O. R. & F. G. EBAUGH, Jr.: The effect of phytohemagglutinin on leukocyte cultures as measured by P³² incorporation in the DNA, RNA and acid-soluble fractions. *Blood* 19 : 443~453, 1962
- 6) ASOFSKY, R. & J. J. OPPENHEIM: Protein synthesis by human leukocytes transformed *in vitro*. *J. Reticuloendothelial Soc.* 3 : 373~374, 1966
- 7) PARENTI, F.; P. FRANCESCHINI, G. FORTI & R. CEPPELLINI: The effect of phytohemagglutinin on the metabolism and X-globulin synthesis of human lymphocytes. *Biochem. Biophys. Acta* 123 : 181~187, 1966
- 8) LING, N. R.: Lymphocyte stimulation. Ch. 13, Sec. 0.2, North Holland, 1968
- 9) WILSON, D. B.: Quantitative studies on the behavior of sensitized lymphocytes *in vitro*. *J. Exp. Med.* 122 : 143~166, 1965
- 10) ASTALDI, G.; G. R. BURGIO, J. KRČ, R. GENOVA & A. A. ASTALDI, Jr.: L-Asparaginase and blastogenesis. *Lancet* 1969-I : 423, 1969
- 11) McELWAIN, T. J. & S. K. HAYWARD: L-Asparaginase and blastogenesis. *Lancet* 1969-I : 527, 1969
- 12) DARTNALL, J. A. & A. G. BAIKIE: L-Asparaginase and blastogenesis. *Lancet* 1969-I : 1098, 1969
- 13) ASTALDI, Jr., A. A.; G. R. BURGIO, J. KRČ, R. GENOVA & G. ASTALDI: Inhibition of the PHA-response by L-asparaginase. *Hematologia* 3 : 395~399, 1969

- 14) UMEZAWA, H.; K. MAEDA, T. TAKEUCHI & Y. OKAMI: New antibiotics, bleomycin A and B. *J. Antibiotics, Ser. A* 19 : 200~209, 1966
- 15) UMEZAWA, H.; M. ISHIZUKA, K. KIMURA, J. IWANAGA & T. TAKEUCHI: Biological studies on individual bleomycins. *J. Antibiotics* 21 : 592~602, 1968
- 16) TAKEUCHI, M. & T. YAMAMOTO: Effects of bleomycin on mouse transplantable tumors. *J. Antibiotics* 21 : 631~637, 1968
- 17) UMEZAWA, H.; M. ISHIZUKA, K. MAEDA & T. TAKEUCHI: Studies on bleomycin. *Cancer* 20 : 891~895, 1967
- 18) ICHIKAWA, T.; I. NAKANO & I. HIROKAWA: Bleomycin treatment of the tumors of penis and scrotum. *J. Urol.* 102 : 699~707, 1970
- 19) TAKETA, C.; A. NAGANO, K. WASHIZU, S. MATSUURA, I. ONO & A. EBHARA: Primary result of bleomycin treatment for epidermoid carcinoma of head and neck. Abstracts of 10th International Cancer Congress, p. 474, No. 767, May 22~29, 1970 (Houston)
- 20) Clinical Screening of Co-operative Group of the European Organization for Research on the Treatment of Cancer: Study of the clinical efficiency of bleomycin in human cancer. *Brit. Med. J.* 1970-2 : 643~645, 1970
- 21) LYNCH, W.E.; R.F. BROWN, T. UMEDA, S.G. LANGRETH & I. LIEBERMAN: Synthesis of deoxyribonucleic acid by isolated liver nuclei. *J. Biol. Chem.* 245 : 3911~3916, 1970
- 22) LYNCH, W.E.: Synthesis of deoxyribonucleic acid by isolated liver nuclei. Dissertation submitted to the Graduate Faculty of the University of Pittsburgh in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Anatomy and Cell Biology, School of Medicine, 1972
- 23) LYNCH, W.E.; T. UMEDA, M. UYEDA & I. LIEBERMAN: Nature of the deoxyribonucleic acid made by isolated liver nuclei. *Biochem. Biophys. Acta* 287 : 28~37, 1972
- 24) WINKELSTEIN, A. & G. G. CRADDOCK: Comparative response of normal thymus and lymph node cells to phytohemagglutinin in culture. *Blood* 29 : 594, 1967
- 25) SUZUKI, H.; K. NAGAI, H. YAMAKI, N. TANAKA & H. UMEZAWA: Mechanism of action of bleomycin. Studies with the growing culture of bacterial and tumor cells. *J. Antibiotics* 21 : 379~386, 1968
- 26) KUNIMOTO, T.; M. HORI & H. UMEZAWA: Modes of action of bleomycin, bleomycin and formycin on HeLa S3 cells in synchronized culture. *J. Antibiotics, Ser. A* 20 : 277~281, 1967
- 27) TOBEY, R. A.: Arrest of Chinese hamster cells in G₂ following treatment with the anti-tumor drug bleomycin. *J. Cell Physiol.* 29 : 259, 1972
- 28) NAGATSU, M.; T. OKAGAKI, R. M. RICHART & A. LAMBERT: Effects of bleomycin on nuclear DNA in transplantable VX-2 carcinoma of rabbit. *Cancer Res.* 31 : 992~996, 1971
- 29) PETTIJOHN, D. & P. HANNAWALT: Evidence for repair-replication of ultraviolet damaged DNA in bacteria. *J. Mol. Biol.* 9 : 395, 1964
- 30) RASMUSSEN, R. E. & R. B. PAINTER: Radiation-stimulated DNA synthesis in cultured mammalian cells. *J. Cell. Biol.* 29 : 11, 1966
- 31) EVANS, R. G. & A. NORMAN: Radiation stimulated incorporation of thymidine into the DNA of human lymphocytes. *Nature* 217 : 455~456, 1968
- 32) LIEBERMAN, M. W.; R. N. BANEY, R. E. LEE, S. SELL & E. FARBER: Studies on DNA repair in human lymphocytes treated with proximate carcinogens and alkylating agents. *Cancer Res.* 31 : 1297~1306, 1971